Filing Overview
Liquidia Corporation filed this Form 8-K on March 14, 2022, reporting an event dated March 11, 2022, under Item 8.01, “Other Events.” The filing concerns the Hatch-Waxman patent litigation brought by United Therapeutics Corporation in the U.S. District Court for the District of Delaware.
Material Litigation Update
- Liquidia had sought summary judgment that specified claims in U.S. Patent Nos. 9,593,066 (the “’066 patent”) and 9,604,901 (the “’901 patent”) were invalid based on collateral estoppel.
- On March 11, 2022, Magistrate Judge Jennifer L. Hall recommended denying Liquidia’s motion because United Therapeutics allegedly did not receive timely notice of the collateral-estoppel argument and because the prior decision involved a different standard of proof.
- Judge Hall stated that her recommendation did not address the validity of the asserted claims or the likelihood that the claims would ultimately be found invalid.
- The parties could object to the recommendation. District Judge Richard G. Andrews was expected to decide whether to adopt it.
- United Therapeutics had previously agreed to entry of judgment that Liquidia did not infringe the ’901 patent based on the court’s claim construction. The ’901 patent was therefore no longer at issue.
- The remaining patents at issue were the ’066 patent and U.S. Patent No. 10,716,793 (the “’793 patent”).
- Trial was scheduled for March 28–30, 2022, with closing arguments scheduled for March 31, 2022.
Financial Information and Outlook
This filing does not provide revenue, profit, cash flow, margins, debt, liquidity, guidance, or other quantitative financial metrics. It also does not provide a financial estimate of the potential impact of the litigation.
Key Risks and Contingencies
The outcome remained contingent on the district court’s decision regarding the magistrate judge’s recommendation and the scheduled trial concerning the ’066 and ’793 patents. The filing does not state the likely outcome, potential damages, commercial consequences, or expected timing of any final resolution.
Investor Verification Points
- Verify whether the district court adopted or rejected Judge Hall’s recommendation.
- Verify the results of the March 2022 trial and any subsequent appeals or settlements.
- Confirm the remaining enforceability and scope of the ’066 and ’793 patents.
- Review later filings for any effect on Liquidia’s product commercialization plans, operating expenses, liquidity, or contingent liabilities.